BG103754A - Заместени 4-арилметилен-2-имино-2,3-дихидротиазоли, техни производни и използването им във фармацията - Google Patents

Заместени 4-арилметилен-2-имино-2,3-дихидротиазоли, техни производни и използването им във фармацията Download PDF

Info

Publication number
BG103754A
BG103754A BG103754A BG10375499A BG103754A BG 103754 A BG103754 A BG 103754A BG 103754 A BG103754 A BG 103754A BG 10375499 A BG10375499 A BG 10375499A BG 103754 A BG103754 A BG 103754A
Authority
BG
Bulgaria
Prior art keywords
dihydrothiazole
cyclobutyl
carbon atoms
dichlorophenyl
optionally substituted
Prior art date
Application number
BG103754A
Other languages
Bulgarian (bg)
English (en)
Inventor
Sharon Cheetham
Frank Kerrigan
Colin Jones
Original Assignee
Knoll Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Gmbh filed Critical Knoll Gmbh
Publication of BG103754A publication Critical patent/BG103754A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG103754A 1997-03-15 1999-09-24 Заместени 4-арилметилен-2-имино-2,3-дихидротиазоли, техни производни и използването им във фармацията BG103754A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9705428.2A GB9705428D0 (en) 1997-03-15 1997-03-15 Therapeutic agents
PCT/EP1998/001358 WO1998041528A1 (fr) 1997-03-15 1998-03-09 4-arylmethylene-2-imino-2,3-dihydrothiazoles substitues, leurs derives, et leur utilisation pharmaceutique

Publications (1)

Publication Number Publication Date
BG103754A true BG103754A (bg) 2000-06-30

Family

ID=10809320

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103754A BG103754A (bg) 1997-03-15 1999-09-24 Заместени 4-арилметилен-2-имино-2,3-дихидротиазоли, техни производни и използването им във фармацията

Country Status (22)

Country Link
US (1) US6187802B1 (fr)
EP (1) EP0970090B1 (fr)
JP (1) JP2001515501A (fr)
KR (1) KR20000076190A (fr)
CN (1) CN1255136A (fr)
AT (1) ATE218573T1 (fr)
AU (1) AU6728898A (fr)
BG (1) BG103754A (fr)
BR (1) BR9808254A (fr)
CA (1) CA2283438A1 (fr)
DE (1) DE69805781D1 (fr)
GB (1) GB9705428D0 (fr)
HU (1) HUP0001508A3 (fr)
ID (1) ID22636A (fr)
IL (1) IL131515A0 (fr)
NO (1) NO994452L (fr)
NZ (1) NZ337378A (fr)
PL (1) PL335696A1 (fr)
SK (1) SK122099A3 (fr)
TR (1) TR199902291T2 (fr)
WO (1) WO1998041528A1 (fr)
ZA (1) ZA982134B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19856965A1 (de) * 1998-12-10 2000-06-15 Bayer Ag Substituierte 2-Imino-thiazoline
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US6372798B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
AU3895300A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
AU3760600A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
MXPA01009468A (es) 1999-03-19 2004-03-19 Knoll Gmbh Tratamiento de hipertension pulmonar.
WO2000056308A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Prevention de maladies cardio-vasculaires
WO2000056311A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Regulation du metabolisme
US6376554B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Method of treating sexual dysfunction
GB9911881D0 (en) * 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
GB9911863D0 (en) * 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
FR2796643B1 (fr) * 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0005789D0 (en) * 2000-03-11 2000-05-03 Knoll Ag Therapeutic agents
AU2002314744A1 (en) 2001-04-17 2002-10-28 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
ATE480235T1 (de) * 2001-12-11 2010-09-15 Univ Virginia Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
US6743797B2 (en) 2002-02-22 2004-06-01 Chantest, Inc. Methods for treating cardiac arrhythmia
US20050054010A1 (en) * 2003-07-15 2005-03-10 Brown Arthur M. High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins
US7211407B2 (en) * 2003-07-15 2007-05-01 Chan Test, Inc. High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins
US20050208595A1 (en) * 2004-03-19 2005-09-22 Brown Arthur M High throughput assay systems and methods for identifying agents that alter expression of cellular proteins
JP2009504748A (ja) * 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション R(+)プラミペキソールを用いた神経回復
US20070203111A1 (en) * 2006-01-06 2007-08-30 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
KR100752757B1 (ko) * 2006-04-05 2007-08-29 한국과학기술연구원 2-페닐이미노-1,3-티아졸린을 포함하는 미백 조성물
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
KR20090021169A (ko) 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 R(+) 및 s(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008113056A2 (fr) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthèse de benzothiazole diamines substituées et purifiées du point de vue chiral
EP2334185A4 (fr) * 2008-08-19 2011-09-21 Knopp Neurosciences Inc Compositions et procédés employant du (r)-pramipexole
KR101049935B1 (ko) * 2008-12-03 2011-07-15 한국과학기술연구원 신규한 티아졸린계 화합물 및 이를 포함하는 t-형 칼슘 채널 저해제
MX2011013577A (es) * 2009-06-19 2012-04-10 Knopp Neurosciences Inc Composiciones y metodos para tratar esclerosis lateral amiotrofica.
WO2013096816A1 (fr) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Synthèse améliorée de composés substitués par amine de 4,5,6,7-tétrahydrobenzothiazole
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
PL3019167T3 (pl) 2013-07-12 2021-06-14 Knopp Biosciences Llc Leczenie podwyższonych poziomów eozynofili i/lub bazofili
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
HUE055850T2 (hu) 2013-08-13 2022-01-28 Knopp Biosciences Llc Készítmények és módszerek a krónikus urticaria (csalánkiütés) kezelésére

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347248A (en) * 1981-03-23 1982-08-31 American Cyanamid Company 2,3-Disubstituted-thiazolo[3,2-a]pyrimidines
US5232921A (en) 1987-03-12 1993-08-03 Sanofi Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions
FR2612187B1 (fr) * 1987-03-12 1989-07-21 Sanofi Sa Derives du thiazole actifs sur le systeme cholinergique, leur procede de preparation et compositions pharmaceutiques en contenant
US5463069A (en) * 1992-12-04 1995-10-31 Sumitomo Chemical Company, Limited Process of producing 2-iminothiazoline derivatives and process of producing their intermediates
CN1113242A (zh) * 1994-04-04 1995-12-13 住友化学工业株式会社 亚氨基噻唑啉衍生物及含有它们作为活性成分的除草剂
GB9513467D0 (en) 1995-07-01 1995-09-06 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
ZA982134B (en) 1999-09-13
ID22636A (id) 1999-12-02
HUP0001508A2 (hu) 2001-01-29
GB9705428D0 (en) 1997-04-30
US6187802B1 (en) 2001-02-13
TR199902291T2 (xx) 1999-12-21
HUP0001508A3 (en) 2003-01-28
ATE218573T1 (de) 2002-06-15
AU6728898A (en) 1998-10-12
DE69805781D1 (de) 2002-07-11
BR9808254A (pt) 2000-05-16
CN1255136A (zh) 2000-05-31
EP0970090A1 (fr) 2000-01-12
SK122099A3 (en) 2000-05-16
EP0970090B1 (fr) 2002-06-05
NO994452D0 (no) 1999-09-14
WO1998041528A1 (fr) 1998-09-24
NO994452L (no) 1999-09-14
CA2283438A1 (fr) 1998-09-24
JP2001515501A (ja) 2001-09-18
NZ337378A (en) 2001-01-26
KR20000076190A (ko) 2000-12-26
PL335696A1 (en) 2000-05-08
IL131515A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
BG103754A (bg) Заместени 4-арилметилен-2-имино-2,3-дихидротиазоли, техни производни и използването им във фармацията
EP1891042B1 (fr) Dérivés de 2-oxo-pyrrolidine, méthodes de préparation et utilisation en tant que médicaments du système nerveux central
SK16852001A3 (sk) Tiazolové deriváty a farmaceutické kompozície ich obsahujúce
KR100305071B1 (ko) 벤질-락탐유도체및/또는벤질리덴-락탐유도체,이들의제조방법및이들의세로토닌1에이및/또는세로토닌1디수용체의선택적인길항제및/또는작용제로서의용도
US20100222326A1 (en) New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders
SK16842001A3 (sk) Substituované imidazotiazoly ako antidepresívne prostriedky
AU603776B2 (en) Isothiazolone derivatives
JPH0710853B2 (ja) チアジン(又はオキサジン)誘導体、その製法及びその合成中間体
KR100417506B1 (ko) 항우울 치료를 위한 5ht1 길항제
HUE026889T2 (en) 2-Oxo-1-imidazolidinyl derivatives imidazotiadiazol
AU631982B2 (en) 5-aryl-4-alkyl-3h-1,2,4-triazole-3-thiones useful as memory enhancers
US5869492A (en) Condensed thiazole derivatives, having 5-HT receptor affinity
JP2006508113A (ja) キノリン誘導体
CZ9903260A3 (cs) Terapeutická činidla
MXPA97009509A (en) Therapeutic agents